HOOK

Shares of biopharmaceutical company Hookipa Pharma (NASDAQ:HOOK) are soaring today on the back of its licensing deal with Roche for HB-700 and a novel immunotherapy (undisclosed). With this move, Hookipa gains an upfront payment of $25 million, a potential optional payment of $15 million for another candidate as well as milestone payments of up to $930 million (apart from sales royalties). Shares are now up ~24.4% over the last five days.
https://www.tipranks.com/news/hookipa-pharma-rises-on-roche-deal?utm_source=advfn.com&utm_medium=referral